Skip to content

Biochemical adaptive radiation therapy based on prostate-specific antigen response in salvage radiation therapy for postoperative biochemical failure of prostate cancer.

Biochemical adaptive radiation therapy based on prostate-specific antigen response in salvage radiation therapy for postoperative biochemical failure of prostate cancer. - Biochemical Adaptive Salvage Radiation Therapy for biochemical failure after radical prostatectomy.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000047536
Enrollment
35
Registered
2022-05-20
Start date
2022-05-17
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

All patients will be prescribed 68 Gy to the prostate bed. Patients are defined as responders and non-responders based on the change in PSA before radiotherapy and on the day of 46 Gy irradiation. T

Sponsors

Kamagaya General Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1 Biochemical failure of a cT1~3bN0~1M0, radical prostatectomy +/- pelvic lymph node dissection. 2 Adenocarcinoma or Tubular adenocarcinoma 3 Performance status0-1 4 I cannot detect a macroscopic lesion in an examination for image at the time of a recurrence diagnosis 5 The thing that is obtained a document agreement by a patient on participating of this study

Exclusion criteria

Exclusion criteria: 1.Prior exposure to any anti-cancer drug and/or hormonal agents. 2.History of pelvic irradiation. 3.Active overlap cancer 4.I have various disorders to impair inspection, treatment 5.In addition, the patient who was judged to be inappropriate as an object by the judgment of the doctor

Design outcomes

Primary

MeasureTime frame
5-year biochemical disease-free survival rate

Secondary

MeasureTime frame
Five years overall survival rate Clinical recurrence style The immediate nature period and close intestinal tract/urinary tract toxicity incidence

Countries

Japan

Contacts

Public ContactToshiki Ohno

Kamagaya General Hospital Radiation therapy

chiken@kamagaya-hp.jp047-498-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026